Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma

Gene Therapy

Volumn 13, Issue 17, 2006, Pages 1263-1271

  Zhang, R ^a,b   Tian, L ^a   Chen, L J ^a   Xiao, F ^a   Hou, J M ^a   Zhao, X ^c   Li, G ^a   Yao, B ^a   Wen, Y J ^a   Li, J ^a   Zhang, L ^a   Chen, X C ^a   Luo, F ^a   Peng, F ^a   Jiang, Y ^a   Wei, Yu Qua ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU MILITARY GENERAL HOSPITAL   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Chemotherapy; Cisplatin; MIG (CXCL9); Tumor angiogenesis

Indexed keywords

ALGINIC ACID; CD31 ANTIGEN; CISPLATIN; CXCL9 CHEMOKINE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INHIBITION KINETICS; LEWIS CARCINOMA; LOW DRUG DOSE; LUNG CARCINOMA; MOUSE; NONHUMAN; OPEN READING FRAME; PLASMID; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR VASCULARIZATION; TUMOR VOLUME; VIRAL GENE THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CARCINOMA, LEWIS LUNG; CHEMOKINE CXCL9; CHEMOKINES, CXC; CISPLATIN; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; GENE THERAPY; GENETIC ENGINEERING; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAPERITONEAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; ONCOLYTIC VIROTHERAPY; PLASMIDS; RANDOM ALLOCATION; T-LYMPHOCYTES, CYTOTOXIC;

MURINAE;

EID: 33747584873     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302756     Document Type: Article

References (49)

1. Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous low-dose anti-angiogenic/metronomic chemotherapy: From the research laboratory into the oncology clinic. Ann Oncol 2002; 13: 12-15.
2. Kamen BA, Rubin E, Aisner J, Glatstein E. High-time chemotherapy or high time for low dose. J Clin Oncol 2000; 18: 2935-2937.
3. Gasparini G. Metronomic scheduling: The future of chemotherapy? Lancet Oncol 2001; 2: 733-740.
4. Boehm T, Folkman J, Browder T, O'Reilly MS. Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
5. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15-R24.
6. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002; 62: 6938-6943.
7. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 1991; 13: 31-36.
8. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878-1886.
9. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-1763.
10. Harris AL. Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy. Recent Res Cancer Res 1998; 152: 341-352.
11. Eckhardt SG, Pluda JM. Development of angiogenesis inhibitors for cancer therapy. Invest New Drug 1997; 15: 1-3.
12. Folkman J. Angiogenesis inhibitors: A new class of drugs. Cancer Biol Ther 2003; 2: S127-S133.
13. Tandle A, Blazer DG, Libutti SK. Antiangiogenic gene therapy of cancer: recent developments. J Transl Med 2004; 2: 22.
14. Rollins BJ. Chemokines. Blood 1997; 90: 909-928.
15. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217-242.
16. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995; 270: 27348-27357.
17. Sgadari C, Farber JM, Angiolillo AL, Liao F, Teruya-Feldstein J, Burd PR et al. Mig, the monokine induced by interferon-γ promotes tumor necrosis in vivo. Blood 1997; 89: 2635-2643.
18. Gasperini S, Marchi M, Calzetti F, Laudanna C, Vicentini L, Olsen H et al. Gene expression and production of the monokine induced by IFN-γ (MIG), IFN-inducible T cell-chemoattractant (I-TAC), and IFN-γ inducible protein-10(IP-10) chemokines by human neutrophils. J Immunol 1999; 162: 4928-4937.
19. Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM. Human Mig chemokine: Biochemical and functional characterization. J Exp Med 1995; 182: 1301-1314.
20. Marx J. Angiogenesis: A boost for tumor starvation. Science 2003; 301: 452-454.
21. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001; 61: 7669-7674.
22. Jin RJ, Kwak C, Lee SG, Lee CH, Soo CG, Park MS et al. The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts. Cancer Gene Ther 2000; 7: 1537-1542.
23. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst 1995; 87: 581-586.
24. Bikfalvi A, Gimenez-Gallego G. The control of angiogenesis and tumor invasion by platelet factor-4 and platelet factor-4-derived molecules. Semin Thromb Hemost 2004; 30: 137-144.
25. Feldman AL, Friedl J, Lans TE, Libutti SK, Lorang D, Miller MS et al. Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer 2002; 99: 149-153.
26. Addison CL, Arenberg DA, Morris SB, Xue YY, Burdick MD, Mulligan MS et al. The CXC chemokine, monokine induced by interferon-γ, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther 2000; 11: 247-261.
27. Angiolillo AL, Sgadari C, Tosato G. A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann NY Acad Sci 1996; 795: 158-167.
28. Soto H, Wang W, Strieter RM, Copeland NG, Gilbert DJ, Jenkins NA et al. The CC chemokine 6-Ckine binds the CXC chemokine receptor CXCR3. Proc Natl Acad Sci USA 1998; 95: 8205-8210.
29. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, et al. Chemokine receptor specific for IP-10 and MIG: Structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184: 963-969.
30. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997; 61: 246-257.
31. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 1388-1393.
32. Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F et al. Low-dose chemotherapy combined with an anti-angiogenic drug reduces human glioma growth in vivo. Cancer Res 2001; 61: 7501-7506.
33. Hou JM, Liu JY, Yang L, Zhao X, Tian L, Ding ZY et al. Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities. Oncology 2005; 69: 81-87.
34. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003; 13: 159-167.
35. Yao B, He QM, Tian L, Xiao F, Jiang Y, Zhang R et al. Enhanced antitumor effect of the combination of tumstatin gene therapy and gemcitabine in murine models. Hum Gene Ther 2005; 16: 1075-1086.
36. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R et al. Expression of the angiogenic factors vascular endothelial growth factor, acidic and basic fibroblast growth factor, tumor growth factor-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963-969.
37. Ruehlmann JM, Xiang R, Niethammer AG, Ba Y, Pertl U, Dolman CS et al. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res 2001; 61: 8498-8503.
38. Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 2003; 63: 8408-8413.
39. Wei YQ, Huang MJ, Yang L, Zhao X, Tian L, Lu Y et al. Immunogene therapy of tumors with vaccine based on xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 2001; 98: 11545-11550.
40. Xiao F, Wei Y, Yang L, Zhao X, Tian L, Ding Z et al. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Therapy 2002; 9: 1207-1213.
41. McAllister F, Steele C, Zheng M, Young E, Shellito JE, Marrero L et al. T cytotoxic-1 CD8+ T Cells are effector cells against pneumocystis in mice. J Immunol 2004; 172: 1132-1138.
42. Tan GH, Tian L, Wei YQ, Zhao X, Li J, Wu Yet al. Combination of low-dose cisplatin and recombination xenogeheic endoglin as a vaccin induses synergistic antitumor activities. Int J Cancer 2004; 112: 701-706.
43. Moorsel CJ, Pinedo HM, Smid K, Comijn EM, Voorn DA, Veerman G et al. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. Eur J Cancer 2000; 36: 2420-2429.
44. He QM, Wei YQ, Tian L, Zhao X, Su JM, Yang L et al. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem 2003; 278: 21831-21836.
45. Hoffmann J, Schirner M, Menrad A, Schneider MR. A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Res 1997; 57: 3847-3851.
46. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6: 1160-1166.
47. Wild R, Ramakrishnan S, Sedgewick J, Griffioen AW. Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: Effects of VEGF-toxin conjugate on tumor microvessel density. Microvasc Res 2000; 59: 368-376.
48. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 9482-9487.
49. Lu Y, Wei YQ, Tian L, Zhao X, Yang L, Hu B et al. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor1. J Immunol 2003; 170: 3162-3170.